Every Form 4 that PROVECTUS BIOPHARMS (PVCT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PVCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PVCT filings page.
PROVECTUS BIOPHARMACEUTICALS, INC. (symbol: PVCT) is the issuer of record for a Form 4 filing submitted to the SEC.
PROVECTUS BIOPHARMACEUTICALS, INC. (symbol: PVCT) is the issuer of record for a Form 4 filing submitted to the SEC.
PROVECTUS BIOPHARMACEUTICALS, INC. (symbol: PVCT) is the issuer of record for a Form 4 filing submitted to the SEC.
For PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), CEO and director Edward Pershing reported derivative conversions involving a 2025 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock. On August 26, 2026 the 2025 Note automatically converted into 11,328 Series D-1 shares at $2.862 per share, and those preferred shares were then converted into 113,280 common shares, reflecting a 10-for-1 conversion ratio. The reported post-transaction holdings of 2,924,949 common shares and related derivative amounts include corrections to typographical errors in a prior Form 4 and those adjustments themselves do not represent new transactions.
PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing filed an updated Form 4 that corrects a past reporting error rather than recording a new transaction. The filing adjusts his reported holdings of Series D-1 Convertible Preferred Stock, with the footnote stating the change "does not reflect a transaction."
After this correction, Pershing is shown holding 2,866,761 shares of Series D-1 Convertible Preferred Stock. Each preferred share is convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier under the certificate of designation terms.
PROVECTUS BIOPHARMACEUTICALS, INC. reported that President and director Dominic Rodrigues received a grant of 45,860 shares of Series D-1 Convertible Preferred Stock at a price of $0.00 per share. Each preferred share is convertible into 10 shares of common stock, representing 458,600 underlying common shares. After this grant, Rodrigues holds 1,383,736 shares of Series D-1 Preferred Stock, which will automatically convert into common stock on December 31, 2028 unless converted earlier under the series’ terms.
PROVECTUS BIOPHARMACEUTICALS, INC. director John Lacey III reported receiving a grant of 48,917 shares of Series D-1 Convertible Preferred Stock on June 30, 2026. The shares were awarded at a price of $0.00 per share as a compensation-related acquisition.
Each Series D-1 share is convertible into 10 shares of common stock, representing 489,170 underlying common shares for this grant. After this award, Lacey holds 228,509 shares of Series D-1 Convertible Preferred Stock. The Series D-1 preferred will automatically convert into common stock on December 31, 2028, unless converted earlier under its certificate of designation.
Provectus Biopharmaceuticals director Bailey Webster received a grant of 48,917 shares of Series D-1 Convertible Preferred Stock. The shares were acquired on June 30, 2026 at a stated price of $0.00 per share as a grant or award, not an open-market transaction.
Each share of Series D-1 Preferred Stock is convertible into 10 shares of Provectus common stock. The Series D-1 Preferred Stock will automatically convert into common stock on December 31, 2028, unless converted earlier under the terms of its Certificate of Designation. Following this grant, Webster directly holds 207,535 shares of Series D-1 Preferred Stock.
PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing exercised convertible securities to increase his common stock holdings. On the transactions date, an 8% unsecured convertible promissory note converted into 9,436 shares of Series D-1 Convertible Preferred Stock at $2.862 per preferred share. Each preferred share is convertible into 10 shares of common stock, resulting in 94,360 additional common shares. After these derivative exercises and conversions, Pershing directly owns 2,857,285 shares of common stock. These were conversions of existing securities, not open-market purchases or sales.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note as a derivative award. The note can be converted into Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share, with 5,242 preferred shares issuable on conversion. The note’s principal and interest will automatically convert into Series D-1 Preferred Stock twelve months after its issue date. Each Series D-1 Preferred share is itself convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing exercised derivative securities to acquire additional common stock. An 8% unsecured convertible promissory note converted into 32,089 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share, then those preferred shares converted into 320,890 shares of common stock. Following these conversions, Pershing directly holds 2,847,849 shares of common stock. These were non‑market derivative conversions, not open‑market purchases or sales.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported a non-market transaction that increases his common stock position through derivative conversions. An 8% unsecured convertible promissory note was converted into 22,651 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share, as described in the financing terms. Each preferred share is convertible into 10 shares of common stock, resulting in 226,510 common shares underlying this conversion. Following these exercises and conversions, Pershing directly holds 2,815,760 shares of common stock, reflecting a larger equity stake obtained through previously agreed financing and conversion features rather than open-market purchases.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing exercised derivative securities related to prior financing arrangements. An 8% unsecured convertible promissory note converted into 18,876 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share. Each preferred share is convertible into 10 shares of common stock, resulting in 188,760 shares of common stock. Following these conversions, Pershing held 2,793,109 shares of common stock directly, with no remaining derivative position from this note.
Provectus Biopharmaceuticals CEO Edward Pershing reported a non-cash conversion of debt into equity. An 8% unsecured convertible promissory note automatically converted into 30,202 shares of Series D-1 Convertible Preferred Stock on April 29, 2026 at a conversion price of $2.862 per share.
Each Series D-1 preferred share is convertible into 10 shares of common stock, so the new preferred position represents 302,020 common shares. After this derivative exercise/conversion, Pershing directly owns 2,774,233 shares of Provectus common stock, with no remaining derivative position shown in this filing.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported two non-market, derivative exercises. An 8% unsecured convertible promissory note, issued under the company’s 2025 financing, was converted into 33,977 shares of Series D-1 Convertible Preferred Stock at $2.862 per share. Each Series D-1 share is convertible into 10 common shares, and on the same date these preferred shares were converted into 339,770 shares of common stock. Following the conversion, Pershing directly owned 2,744,031 shares of common stock. The Series D-1 preferred would otherwise automatically convert into common stock on December 31, 2028, unless converted earlier under its terms.
Provectus Biopharmaceuticals CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note that can be converted into 17,471 shares of Series D-1 Convertible Preferred Stock. The note may be voluntarily converted into Series D-1 Preferred at a price of $2.862 per share at any time while outstanding.
According to the disclosure, any outstanding principal and interest on the note will automatically convert into Series D-1 Preferred at the same $2.862 price per share twelve months after the note’s issue date. Each Series D-1 Preferred share is itself convertible into 10 shares of common stock and will automatically convert to common stock on December 31, 2028, unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported non‑market transactions converting debt and preferred equity into common stock. An 8% unsecured convertible promissory note converted into 49,067 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share. Those 49,067 Series D-1 shares were then converted into 490,670 shares of common stock, reflecting the 10:1 conversion ratio. Following these conversions, Pershing directly holds 2,710,054 shares of common stock. The Series D-1 Preferred Stock is also described as automatically converting into common stock on December 31, 2028 unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note. The note allows him to convert outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at $2.862 per share, with automatic conversion into Series D-1 Preferred twelve months after the issue date. Each Series D-1 Preferred share is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported acquiring an 8% unsecured convertible promissory note as a derivative security. The note was issued under the company’s 2025 Financing and does not immediately involve common shares, but it can later convert into equity.
The footnotes state that the outstanding principal and interest of the note may be converted into shares of Series D-1 Convertible Preferred Stock at a price per share of $2.862, either voluntarily at any time or automatically twelve months after the issue date. Each Series D-1 Preferred share is in turn convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing reported the grant of an 8% unsecured convertible promissory note. The note may be voluntarily converted into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share while it is outstanding.
The outstanding principal and interest will automatically convert into Series D-1 Preferred Stock at $2.862 per share twelve months after the note’s issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on December 31, 2028 unless converted earlier.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported a non-cash conversion of an 8% unsecured convertible promissory note into 47,180 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share on February 20, 2026.
Each Series D-1 Preferred share is convertible into 10 common shares and will automatically convert into common stock on December 31, 2028, unless converted earlier under its certificate of designation. Following this transaction, Pershing directly owned 2,660,987 Series D-1 Preferred shares.
Provectus Biopharmaceuticals CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note. This derivative security allows him to convert the note’s outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share at any time while the note is outstanding.
The footnotes state that, twelve months after the note’s issue date, the outstanding principal and interest will automatically convert into Series D-1 Preferred Stock at the same $2.862 conversion price. Each Series D-1 Preferred share is then convertible into 10 shares of Provectus common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier under its terms.
Provectus Biopharmaceuticals CEO Edward Pershing reported acquiring an 8% unsecured convertible promissory note from the company on February 12, 2026. The note has a principal amount of $30,000 and may be converted into Series D-1 Convertible Preferred Stock at $2.862 per share.
The outstanding principal and interest on the note will automatically convert into Series D-1 preferred stock twelve months after the note’s issue date. Each Series D-1 preferred share is convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.
Pershing Edward reported open-market purchase transactions in a Form 4 filing for PVCT. The filing lists transactions totaling 34,940 shares at a weighted average price of $2.86 per share. Following the reported transactions, holdings were 2,613,807 shares.
Provectus Biopharmaceuticals CEO Edward Pershing, who also serves as a director, reported receiving an 8% unsecured convertible promissory note on February 5, 2026. The note can be converted into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
Under the terms described, each share of Series D-1 preferred is convertible into 10 shares of common stock. The Series D-1 preferred will automatically convert into common stock on December 31, 2028, unless it is converted earlier under its certificate of designation.
Provectus Biopharmaceuticals CEO Edward Pershing converted debt into equity-linked securities. On January 30, 2026, an 8% unsecured convertible promissory note called the 2025 Note converted into 37,744 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on June 20, 2026 unless converted earlier under its terms. After this transaction, Pershing directly beneficially owned 2,578,867 shares of Series D-1 Convertible Preferred Stock.
Provectus Biopharmaceuticals CEO and director Edward Pershing reported acquiring an 8% unsecured convertible promissory note on January 28, 2026. The note can be converted at any time into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
The note’s outstanding principal and interest will automatically convert into Series D-1 Convertible Preferred Stock twelve months after its issue date, pursuant to the company’s 2025 Financing. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock and will automatically convert into common stock on June 26, 2026, unless converted earlier under its terms.
Provectus Biopharmaceuticals CEO Edward Pershing reported a debt-for-equity conversion tied to prior financing. On January 16, 2026, an 8% unsecured convertible promissory note with $100,000 of outstanding principal and interest converted into 37,744 shares of Series D-1 Convertible Preferred Stock at $2.862 per share under the issuer's 2025 Financing. Each share of this preferred stock is convertible into 10 shares of common stock, and the Series D-1 Convertible Preferred Stock will automatically convert into common stock on June 20, 2026, unless converted earlier under its terms. Following this transaction, Pershing directly beneficially owned 2,541,123 derivative securities as reported in the Form 4.
Provectus Biopharmaceuticals, Inc. CEO and director Edward Pershing reported an insider transaction dated 12/11/2025 involving an 8% unsecured convertible promissory note. This note is treated as a derivative security linked to the company’s Series D-1 Convertible Preferred Stock.
Pershing may elect at any time to convert the note’s outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share. If he does not act earlier, the note will automatically convert into Series D-1 Preferred Stock twelve months after its issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock and will automatically convert into common stock on June 26, 2026, unless converted sooner according to its terms.
Provectus Biopharmaceuticals, Inc. reported an insider financing transaction involving its CEO and director, Edward Pershing. On 12/05/2025, he acquired an 8% unsecured convertible promissory note with an amount of $ 75,000. The note can be converted at any time into shares of Series D-1 Convertible Preferred Stock at a price of $ 2.862 per share, and will automatically convert into that preferred stock twelve months after its issue date as part of the company’s 2025 Financing.
Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of Provectus common stock. The Series D-1 preferred shares will automatically convert into common stock on June 26, 2026, unless converted earlier under the terms of the Series D-1 Certificate of Designation. This transaction increases the CEO’s potential future equity exposure through layered conversions from debt to preferred stock and then to common shares.
Provectus Biopharmaceuticals, Inc. reported a Form 4 transaction by its CEO and director, Edward Pershing, involving an 8% unsecured convertible promissory note tied to the company’s 2025 financing. On 11/26/2025, the reporting person acquired a note with principal of $70,000 that is convertible into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
The filing states that the note’s outstanding principal and interest may be converted into Series D-1 Preferred Stock at any time while it is outstanding, and will automatically convert at the same price per share twelve months after the note’s issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred shares will automatically convert into common stock on June 26, 2026, unless converted earlier under their terms.
Provectus Biopharmaceuticals, Inc. (PVCT) reported an insider financing transaction by CEO and director Edward Pershing. On 11/20/2025, Pershing acquired an 8% unsecured convertible promissory note with a principal amount of $30,000, convertible into Series D-1 Convertible Preferred Stock at $2.862 per share. This allows voluntary conversion of the note’s outstanding principal and interest into Series D-1 Preferred at that price while the note is outstanding, and it will automatically convert into preferred shares twelve months after the issue date.
Each share of Series D-1 Preferred is convertible into 10 shares of PVCT common stock. The Series D-1 Preferred will automatically convert into common stock on June 26, 2026, unless converted earlier under its terms. The transaction is part of the issuer’s 2025 financing.
Provectus Biopharmaceuticals (PVCT) CEO and director reported acquiring an 8% unsecured convertible promissory note on 11/13/2025. The note’s outstanding principal and interest may be converted into Series D-1 Convertible Preferred Stock at $2.862 per share, and will automatically convert at that price twelve months after the issue date.
Table II lists an underlying amount of 10,483 shares of Series D-1 Preferred. Each Series D-1 Preferred share is convertible into 10 shares of common stock. The Series D-1 Preferred will automatically convert into common stock on June 26, 2026, unless converted earlier under its terms.
Provectus Biopharmaceuticals (PVCT) CEO and director Edward Pershing filed a Form 4 reporting an insider transaction on 11/06/2025. He acquired an 8% unsecured convertible promissory note issued under the company’s 2025 Financing.
The note may be converted into Series D‑1 Convertible Preferred Stock at $2.862 per share, and will automatically convert twelve months after the issue date. The filing lists 12,230 shares of Series D‑1 Preferred as the securities underlying the note. Each Series D‑1 Preferred share is convertible into 10 shares of common stock, and the preferred automatically converts to common on June 26, 2026 unless converted earlier.
Provectus Biopharmaceuticals (PVCT) CEO and Director Edward Pershing reported acquiring an 8% unsecured convertible promissory note with a principal amount of $65,000 on 10/30/2025.
The note is convertible at a price of $2.862 per share into Series D-1 Convertible Preferred Stock, representing 22,712 preferred shares. The note’s outstanding principal and interest will automatically convert into Series D-1 Preferred at $2.862 on the date that is twelve months after issuance. Each Series D-1 Preferred share converts into 10 shares of common stock and will automatically convert into common stock on June 26, 2026, unless converted earlier per its terms.
Following the reported transaction, $1,180,000 of derivative securities were beneficially owned, held directly.
Provectus Biopharmaceuticals (PVCT) CEO and director Edward Pershing reported a transaction on 10/23/2025 involving an 8% unsecured convertible promissory note. The note may be converted at a price of $2.862 per share into Series D-1 Convertible Preferred Stock.
The outstanding principal and interest of the note will automatically convert into Series D-1 Preferred twelve months after the issue date. Each share of Series D-1 Preferred is convertible into 10 shares of common stock, and the Series D-1 Preferred will automatically convert into common stock on June 26, 2026, unless converted earlier according to its terms.
Provectus Biopharmaceuticals (PVCT) CEO and director reported a non-cash conversion on 10/16/2025. An 8% unsecured convertible promissory note issued in 2024 converted into 18,880 shares of Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per preferred share. Each preferred share is convertible into 10 common shares, equating to 188,800 underlying common shares. The Series D-1 Preferred will automatically convert into common stock on June 20, 2026, unless converted earlier.
Provectus Biopharmaceuticals (PVCT) reported an insider transaction by its CEO and Director. On 10/10/2025, the reporting person acquired an 8% unsecured convertible promissory note. The note is convertible at $2.862 per share into Series D-1 Convertible Preferred Stock, with 20,965 preferred shares shown as the underlying amount. The note’s outstanding principal and interest will automatically convert into Series D-1 Preferred twelve months after its issue date. Each Series D-1 Preferred share converts into 10 common shares and will automatically convert into common stock on June 26, 2026, unless converted earlier per its terms.
Edward Pershing, CEO and director of Provectus Biopharmaceuticals, Inc. (PVCT), reported a securities transaction on 10/03/2025. He acquired an 8% unsecured convertible promissory note with a principal amount of $35,000 that is convertible into Series D-1 Convertible Preferred Stock at a fixed conversion price of $2.862 per share. The Note may be voluntarily converted any time while outstanding and will automatically convert into Series D-1 Preferred Stock twelve months after issuance on 10/03/2026. The filing shows 12,230 shares of Series D-1 Preferred Stock reported as beneficially owned after the transaction and a stated aggregate amount of $1,085,000 associated with that class. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock and will automatically convert into common stock on 6/26/2026 unless earlier converted.